Abstract
Cycloleucine (1-aminocyclopentane carboxylic acid) was shown to be quite active in preventing the clinical and histologic signs of experimental allergic encephalomyelitis and adjuvant arthritis. In contrast, it was inactive in two in vitro models designed to detect various types of clinically effective anti-inflammatory, anti-immune agents: tissue culture growth and polymorphonuclear leukocyte migration. Its immunopharmacologic spectrum differs from that of other clinically active agents, suggesting that it may work via a different mechanism or at a different site.
Footnotes
- Received May 21, 1971.
- Accepted October 9, 1971.
- © 1972 by The Williams & Wilkins Co.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.